FibroBiologics Inc [FBLG] stock is trading at $0.66, up 9.04%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The FBLG shares have gain 9.89% over the last week, with a monthly amount drifted -30.96%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
FibroBiologics Inc [NASDAQ: FBLG] stock has seen the most recent analyst activity on December 12, 2024, when Rodman & Renshaw initiated its Buy rating and assigned the stock a price target of $12. Previously, H.C. Wainwright started tracking the stock with Buy rating on October 30, 2024, and set its price target to $12. On September 24, 2024, Maxim Group initiated with a Buy rating and assigned a price target of $12 on the stock.
FibroBiologics Inc [FBLG] stock has fluctuated between $0.58 and $5.62 over the past year. Currently, Wall Street analysts expect the stock to reach $9 within the next 12 months. FibroBiologics Inc [NASDAQ: FBLG] shares were valued at $0.66 at the most recent close of the market. An investor can expect a potential return of 1263.64% based on the average FBLG price forecast.
Analyzing the FBLG fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.67, Equity is -5.64 and Total Capital is -4.61. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.54.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.6249 points at the first support level, and at 0.5897 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.6803, and for the 2nd resistance point, it is at 0.7005.
Ratios To Look Out For
For context, FibroBiologics Inc’s Current Ratio is 1.14. In addition, the Quick Ratio stands at 1.14 and the Cash Ratio stands at 1.06.
Transactions by insiders
Recent insider trading involved Khoja Hamid, Chief Scientific Officer, that happened on May 27 ’25 when 20000.0 shares were purchased. Chief Executive Officer, O’HEERON PETE completed a deal on Aug 12 ’24 to buy 8500.0 shares. Meanwhile, Chief Scientific Officer Khoja Hamid bought 10000.0 shares on Aug 12 ’24.
